Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q3 2014 · 10-Q
Revenue—
Net Income-$3.53M-$3.53MN/M vs Q3 2013 EPS Diluted-$0.08-$0.08N/M vs Q3 2013 Operating Income-$3,545,000N/M Operating Cash Flowderived-$1,672,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,672,000— ended Sep 30, 2014 · filed Nov 5, 2014 · 36 d after period end